Human epidermal growth factor receptor 2/neu protein expression in meningiomas: An immunohistochemical study

Telugu, Ramesh Babu; Chowhan, Amit Kumar; Rukmangadha, Nandyala; Patnayak, Rashmi; Phaneendra, Bobbidi Venkata; Prasad, Bodapati Chandra Mowliswara; Reddy, Munish

doi:10.4103/0976-3147.188640

Cited by 7 publications

(11 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The NIS-ELEMENTS software (Nikon, Tokyo, Japan) was employed to evaluate the intensity and scope of immunohistochemical staining as follows: according to the ratio of EPCAM positive cells: 0% was scored 0, <25% was scored 1, 25-50% was scored 2, 50-75% was scored 3, 75-100% was scored 4; according to the staining intensity: weakly positive = 1, moderately positive = 2, strongly positive = 3. The immunization score was the score of staining intensity multiply the score of ratios of positive cells, which ranged from 0 to 12 [16].…”

Section: Immunohistochemistrymentioning

confidence: 99%

RETRACTED ARTICLE: Silencing of EPCAM suppresses hepatic fibrosis and hepatic stellate cell proliferation in mice with alcoholic hepatitis via the PI3K/Akt/mTOR signaling pathway

et al. 2019

View full text Add to dashboard Cite

Alcoholic hepatitis (AH) is a severe condition developed in patients with underlying alcoholic liver disease. Epithelial cell adhesion molecule (EPCAM) plays a role in hepatitis. Therefore, the current study aimed to explore the effect of EPCAM and its potential mechanism in AH. Bioinformatic analysis was performed to screen differentially expressed genes associated with AH. AH mouse models were established through a Lieber-DeCarli liquid diet containing 4% ethanol, which were co-treated with siRNA against EPCAM or the PI3K/Akt/mTOR signaling pathway inhibitor in order to investigate the effects of EPCAM and the PI3K/Akt/mTOR signaling pathway on hepatic fibrosis, hepatic stellate cell (HSC) proliferation and apoptosis. The relationship between EPCAM and the PI3K/Akt/mTOR signaling pathway was investigated for the purposes of elucidating the potential mechanism of EPCAM in AH. EPCAM was predicted to regulate AH progression through the PI3K/ Akt/mTOR signaling pathway. Silencing EPCAM or inhibition of the PI3K/Akt/mTOR signaling pathway inhibited the hepatic fibrosis and HSC proliferation yet induced HSC apoptosis. Moreover, silencing EPCAM was found to repress the PI3K/Akt/mTOR signaling pathway as evidenced by decreased levels of Bcl2 yet increased levels of caspase-3. Collectively, silencing EPCAM could hinder AH progression by inhibiting the PI3K/Akt/mTOR signaling pathway, which might serve as a potential therapeutic target for AH treatment.

show abstract

Section: Immunohistochemistrymentioning

confidence: 99%

RETRACTED ARTICLE: Silencing of EPCAM suppresses hepatic fibrosis and hepatic stellate cell proliferation in mice with alcoholic hepatitis via the PI3K/Akt/mTOR signaling pathway

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In a 2008 study by Durand et al, on human meningiomas, [20] the association of the expression of HER2 gene with gradient and histologic grade of the tumor was investigated that the levels of mRNA of this gene did not correlate with histological grade. One study [7] on 100 samples of meningioma (including 80 samples of Grade Ӏ, 18 of Grade ӀӀ, and 2 of Grade ӀӀӀ) investigated the association between HER2 expression and sex, location, grade, and subtypes of meningiomas. According to the results of this study, HER2 positivity was seen in 73% of the samples (75% of Grade Ӏ, 72.2% of Grade ӀӀ, and 0% of Grade ӀӀӀ samples).…”

Section: Discussionmentioning

confidence: 99%

“…[1,3] The human epidermal growth factor receptor 2 (HER2), also known as ErbB2, is a 185-kD transmembrane glycoprotein with tyrosine kinase activity expressed in meningiomas and various other tumors. [7] HER2 status is important in the medical management of patients with various human cancers [8] and can be a therapeutic target with monoclonal antibodies for meningiomas that interact with HER2 receptors, [1,9] but the prognostic value of this receptor protein in meningiomas is ambiguous. [10,11] This study aimed to evaluate the HER2 expression in meningiomas and the correlation between this expression and age, gender, and grade.…”

Section: Introductionmentioning

confidence: 99%

Expression of Human Epidermal Growth Factor Receptor 2 in Meningiomas

Ramezani

Firoozabadi

Rezaei

et al. 2020

Indian Journal of Medical and Paediatric Oncology

View full text Add to dashboard Cite

Background: Meningiomas consist of 15%-30% of the primary intracranial tumors, and high-grade meningiomas have a higher recurrence after surgery. The human epidermal growth factor receptor 2 (HER2) status is important in the medical management of patients with various human cancers. This study aimed to evaluate HER2 expression in meningiomas and the correlation between this expression and age, gender, and grade. Materials and Methods: In a descriptive-analytic study, immunohistochemistry (IHC) with HER2 marker was done on confirmed cases of meningioma which were referred to the pathology laboratory from 2008 to 2015. The primary antihuman antibody against c-erbB-2 oncoprotein (DAKO Diagnostics) was used for IHC. Results: Of 117 patients, 68.4% were males. The mean age of the patients was 53.6 years. Grades I, II, and III tumors were 90.6%, 8.5%, and 0.9% of cases, respectively. Totally, 76 (65%) of patients were HER2 positive, with only 7.7% of highly expressed HER2. There was no significant correlation between the mean age (P = 0.672), age group (P = 0.256), sex (P = 0.574), and grade (P = 0.093) and HER2 expression status. Conclusions: We did not find a statistically significant correlation between age, sex, or grade and HER2 status; however, further studies with a higher number of Grades II and III meningiomas and using the fluorescent in situ hybridization in equivocal cases may be of benefit in this way.

show abstract

“…The World Health Organization report of 2016 classifies meningiomas as grades I, II and III ( 3 ). Even grade I tumors recur with frequency ( 4 ) from 7 to 20% ( 5 ), particularly in younger patients and males ( 6 , 7 ).…”

Section: Introductionmentioning

confidence: 99%

Recurrence/Regrowth in Grade I Meningioma: How to Predict?

Carvalho

Silva-Martins

Magalhães³

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

The HLA-G and HLA-E molecules, Ki67, progesterone (PR), estrogen (ER) and androgen receptors (AR), p53, COX-2, and HER2 were studied to assess whether the biological behavior of grade I meningiomas is related to their expression. Tissue samples from 96 patients with grade I intracranial meningiomas were analyzed by immunohistochemistry on tissue microarray blocks (TMA) using antibodies specific for HLA-G, HLA-E, Ki67, PR, ER, AR, p53, COX-2, and HER2. Meningiomas were classified as small (≤2 cm, 1.0%), medium (>2 and ≤4 cm, 32.3%), and large (>4 cm, 66.7%). Tumor size was not related to recurrence/regrowth (p = 0.486), but was significantly correlated with peritumoral edema (p = 0.031) and intratumoral calcifications (p = 0.018). Recurrent meningiomas were observed in 14.6% of cases. Immunostaining for each marker was: HLA-G 100%; HLA-E 95.6%; PR 62%; ER 2.1%; AR 6.5%; p53 92.6%; COX-2 100%; HER2 0%; Ki67, mean 2.61 ± 2.29%, median 2.1%. Primary and recurrent meningiomas showed no significant relation with HLA-E and hormone receptors (p > 0.05), except for Ki67, where a higher median was observed in recurrent tumors than in primary (p = 0.014). The larger the tumor, the more severe the peritumoral edema, and the greater the presence of calcifications. Ki67 appears to be a good biomarker of recurrence/regrowth in grade I meningiomas.

show abstract

Human epidermal growth factor receptor 2/neu protein expression in meningiomas: An immunohistochemical study

Cited by 7 publications

References 19 publications

RETRACTED ARTICLE: Silencing of EPCAM suppresses hepatic fibrosis and hepatic stellate cell proliferation in mice with alcoholic hepatitis via the PI3K/Akt/mTOR signaling pathway

RETRACTED ARTICLE: Silencing of EPCAM suppresses hepatic fibrosis and hepatic stellate cell proliferation in mice with alcoholic hepatitis via the PI3K/Akt/mTOR signaling pathway

Expression of Human Epidermal Growth Factor Receptor 2 in Meningiomas

Recurrence/Regrowth in Grade I Meningioma: How to Predict?

Contact Info

Product

Resources

About